

ABSTRACT TEMPLATE for Company Presentations

The maximum number of words for this abstract is 300 words.

You may delete the section instructions, leaving only the bolded bullet title.

Questions for categories: Biotech/Pharma or Medical Devices or Health IT/Digital

- **Investment Rational**

Briefly describe the company's technology or therapeutic focus; the market opportunity, progress made to date, key partnerships or joint ventures; and management strengths.

The first and only disposable, portable and remote enabled robotic system. These unique features allow access to multiple stakeholders to a technology that has the potential to solve unmet needs in the endoluminal vascular space with a total addressable market of over 5M procedures in the USA alone.

- **Business Strategy**

Briefly describe how the company will apply its core technology, generate short-term and long-term revenues.

Removing the capital component barrier will accelerate the adoption of the technology by healthcare systems, as the robotic system will be available as single-use kits. A modular offering will ensure compatibility with peripheral vascular procedures, followed shortly with neuro and coronary procedures. In the longer term, adding dedicated tools and Big Data capabilities will contribute to the robotic system's broader eco-system.

- **Core Technology**

What is the technology, its uniqueness, and its value proposition?

The unique system allows access for a wide range of over the shelf tools while democratizing these procedures. It has the potential to save procedure time, reduce cost by reducing the instruments used, reduce radiation exposure to the patient and the user, reduce users physical strain and reduce exposure to hospital acquired infections.

- **Product Profile/Pipeline**

Briefly describe the company's product/pipeline, current status and market potential. Discuss milestones, potential collaborations and partnerships.

Initiating pre-clinical trial in Q3 of 2022. Clinical trial to commence in Q4 2022. We hope to commence commercialization in Q4 2023. Microbot recently entered into strategic collaboration with Stryker Corporation.

- **What's Next?**

Complete the pre-clinical, clinical and regulatory process, establish sales and marketing core capabilities for commercialization in 2024.